Evidence map›Paper›PMID 19456219›Full record

ArticleTwin research and human genetics : the official journal of the International Society for Twin Studies2009

Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Sharon E Johnatty, Jonathan Beesley, Xiaoqing Chen, Amanda B Spurdle, Anna Defazio, Penelope M Webb, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Ellen L Goode, David N Rider and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Twin research and human genetics : the official journal of the International Society for Twin Studies, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genetic Variants ofInternational journal of molecular sciences · 2021
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Sharon E JohnattyQueensland Institute of Medical Research, Brisbane, Queensland, Australia.
Jonathan Beesley
Xiaoqing Chen
Amanda B Spurdle
Anna Defazio
Penelope M Webb
Australian Ovarian Cancer Study Group
Australian Cancer Study (Ovarian Cancer)
Ellen L Goode
David N Rider
Robert A Vierkant
Stephanie Anderson
Anna H Wu
Malcolm Pike
David Van Den Berg
Kirsten Moysich
Roberta Ness
Jennifer Doherty
Mary-Anne Rossing
Celeste Leigh Pearce
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute · AUUniversity of Southern California · USMayo Clinic · USFred Hutch Cancer Center · USPeter MacCallum Cancer Centre · AURoswell Park Comprehensive Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Steroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSU01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1996 to 2000
$943k
The Progesterone Receptor Gene and Ovarian Cancer RiskR03CA113148 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PEARCE, CELESTE LEIGH · 2004 to 2005
$163k
CASE-CONTROL STUDY OF OVARIAN CANCER IN LOS ANGELESR01CA061132 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1993 to 1997
–
NCI NIH HHS CA14089NCI NIH HHS CA17054NCI NIH HHS CA61132NCI NIH HHS CA63464NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA87538NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS U01 CA063464
6 · The paper itself

Abstract

Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analyzed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p < .05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.

Indexed as

Polymorphism, GeneticAustraliaCase-Control StudiesFemaleFibroblast Growth Factor 2HumansOvarian NeoplasmsPopulation GroupsRisk FactorsSerous MembraneUnited StatesFibroblast Growth Factor 2

Identifiers

PMID19456219
PMCPMC2844121
OpenAlexW1976528726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.